Chinese Covid-19 Sinopharm vaccine offers poor protection among elderly, finds study

The Chinese Covid-19 Sinopharm vaccine offers poor protection to the elderly, a new study has found.

A new study suggests that a Sinopharm vaccine offers poor protection from Covid-19 among the elderly, raising questions for dozens of countries that have given the Chinese company’s shots to their most vulnerable populations. A survey of blood samples taken from 450 people in Hungary at least two weeks after their second Sinopharm dose found that 90 per cent under 50 years old developed protective antibodies. But the percentage declined with age, and 50 per cent of those over 80 had none.